A biweekly summary of new trial data, guideline recommendations and expert opinion across diabetes care, run by Diabetes Knowledge in Practice (www.knowledgeinpractice.eu). This podcast is intended for healthcare professionals only.
Featuring interviews with leading experts from across the globe.
This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.
Featuring an interview with Professor Tina Vilsboll.
Rapid achievement of glycaemic targets has been a key goal of treatment in diabetes, but does it matter how quickly we achieve this? Based on guidelines, trial evidence and real-world studies, the answer is a resounding "yes". Tune in to this episode to learn outcome improvements associated with early, intensive therapy, and how to achieve this in your clinic.
Davies MJ, et al. Diabetes Care 2018; 41(12):2669-2701
Buse JB, et al. Diabetologia. 2020; 63(2):221-228.
Thomas MC. Adv Chronic Kidney Dis. 2014; 21(3):311-7
Laiteerapong N, et al. Diabetes Care. 2019; 42(3):416-426
Paul SK, et al. Cardiovasc Diabetol. 2015;14:100.
Reaven PD, et al. N Engl J Med 2019; 380:2215-2224
Khunti K, Millar-Jones D. Prim Care Diabetes. 2017;11(1):3-12.
Featuring an interview with Professor David Matthews, President of the EASD.
How should we consider individual factors when setting multifactorial targets - and once these are set, how should we prioritise achieving them? Catch up on the latest guideline recommendations across glycaemic, lipid and blood pressure targets and how these should be met in clinical practice.
Consentino F, et al. Eur Heart J, 2020; 41(2): 255–323
Buse JB, et al. Diabetes Care 2019 Dec; dci190066.
ADA. Diabetes Care 2020; 43(Suppl 1): S1-S2
Rounding off our first season of the podcast, we join Dr Vanita Aroda of Brigham and Women's Hospital for a discussion of future trends in diabetes management. Take a quick walk down memory lane of how practice has changed, and the direction the next decade could head.
Davies MJ, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018; 41(12):2669-2701.
Rowley WR, et al. Diabetes 2030: Insights from Yesterday, Today, and Future Trends. Popul Health Manag. 2017;20(1):6–12.
Kerr D, et al. Diabetes and technology in 2030: a utopian or dystopian future? Diabet Med. 2018; 35(4):498-503.
ESC. New apps for atrial fibrillation. Available online.
Kebede MM, Pischke CR. Popular Diabetes Apps and the Impact of Diabetes App Use on Self-Care Behaviour: A Survey Among the Digital Community of Persons With Diabetes on Social Media [published correction appears in Front Endocrinol (Lausanne). 2019 Apr 05;10:220]. Front Endocrinol (Lausanne). 2019;10:135.
Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018; 18:3-14.
Vuylsteke V, et al. Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes. Drugs R D. 2015;15(3):227–232.
Featuring an interview with Professor Rudy Bilous.
Pregnancy presents a number of considerations for people with diabetes. In addition, a population of pregnant people can develop a transient state of hyperglycaemia called gestational diabetes mellitus, or GDM. In this session, we explore how to diagnose GDM, and why glucose control is so important for both mother and child.
Featuring and interview with EASD President, Professor David Matthews.
Join us for an end-of-year review of the biggest trials of 2019, plus a detailed interview with Professor Matthews about key data, what the future may entail, and the debate surrounding the ESC 2019 guidelines.
CARMELINA: Rosenstock J, et al. JAMA 2019; 321(1):69-79
CAROLINA: Rosenstock J, et al. JAMA 2019; 322(12):1155-1166
CREDENCE: Perkovic V, et al. N Engl J Med 2019; 380:2295-2306
DAPA-HF: McMurray JV, et al. N Engl J Med 2019; 381:1995-2008
PIONEER 6: Husain M, et al. N Engl J Med 2019; 381:841-851
REWIND: Gerstein HC, et al. Lancet. 2019; 394(10193):121-130
ESC guidelines: Consentino F, et al. Eur Heart J, 2019; ehz486
Featuring an interview with Dr Alexander Miras of Imperial college London.
This episode takes a closer look at clinical inertia, and how even a 1 year delay in treatment intensification can lead to significantly increased risk of poor patient outcomes.
Khunti S, et al. Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia. Ther Adv Endocrinol Metab. 2019;10:2042018819844694.
Lin J, et al. Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US. Clinicoecon Outcomes Res. 2016;9:19–29.
Khunti K, Millar-Jones D. Clinical inertia to insulin initiation and intensification in the UK: A focused literature review. Prim Care Diabetes. 2017 Feb;11(1):3-12.
Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36(11):3411–3417.
Featuring an expert interview with Professor Richard Holt.
Over recent years, mental health has gained attention as an important factor for both quality of life, and success for management of chronic conditions such as diabetes. Research is increasingly demonstrating a relationship between mental health disorders and diabetes, with bidirectional causal relationships suspected across the spectrum of care. Join us for a discussion of stressors in diabetes, and how you can help patients recognise and manage their mental health.
Featuring an interview with Dr Philip Burgess, this session focuses on the importance of maintaining eye health in people with diabetes. Retinopathy-induced loss of vision is a common and preventable comorbidity of diabetes, and can be caught and treated early through annual checkups. Learn how to work together with ophtalmology services to help patients maintain their vision.
Featuring an interview with Mr Graham Bowen, clinical lead for podiatry in Southampton.
Diabetic foot disease is a combination of various arterial and/or neurological syndromes that leads to poor circulation and sensation in the lower extremities. As a result, minor foot problems (such as cuts and bruises) can develop into severe infected ulcerations and, ultimately, amputation. In this episode, we explore data surrounding the pathogenesis of poor outcomes, and practical techniques to minimise risk among people with diabetes.
Featuring an interview with Prof Alberico Catapano.
Dyslipidaemia commonly co-occurs with type 2 diabetes, and is a major risk factor for cardiovascular disease. To prevent this condition, all recent guidelines recommend reducing LDL cholesterol concentrations in the blood to near-normal levels, particularly in those with elevated cardiovascular risk. This episode provides a quick overview of dyslipdaemia in diabetes before Prof Alberico Catapano provides his top tips for helping patients bring lipids under control.
A series of expert interviews conducted at EASD 2019. This includes:
Professor Steve Bain, discussing the PIONEER trials of oral semaglutide
Professor Dr Thomas Danne, discussing approaches to type 1 diabetes management
Professor Jens Juul Holst, discussing gastric peptides as actionable targets
Professor Didac Maruicio, discussing the CONCLUDE trial
Featuring an expert interview with Professor Steve Bain. This episode summarises the major diabetes-related announcement at the 2019 ESC Congress in Paris. This includes the DAPA-HF trial, the new ESC guidelines (developed in collaboration with the EASD) and special population studies.
With the ESC 2019 Congress and EASD Annual Meeting taking place over this month, we are slightly changing the release schedule. Our team will be attending both meetings to produce special episodes summarising key highlights, which will be released ~1 week after each conference.
Stay tuned for more information
Featuring an interview with Dr William Alazawi.
Non-alcoholic fatty liver disease (NAFLD) is of increasing concern among people with type 2 diabetes. This condition, where an abnormal amount of fat is stored in liver cells, is associated with non-alcohol steathepatitis (NASH), which in turn can progress to fibrosis, cirrhosis and liver cancer. This episode provides a quick overview of NASH in diabetes before Dr William Alazawi, clinical lead for NASH for the Bart's Health NHS trust, provides his recommendations for patients with abnormal liver function.
Featuring an interview with Professor Ronald Goldenberg.
An overview of the co-occurrence of obesity and diabetes. This includes the effects of bariatric surgery, the underlying genetic factors of obesity, and recommended treatment approaches. Professor Goldenberg discusses practical advice for working together with patients to achieve normalisation of body weight and blood glucose
Featuring an interview with Professor Carel le Roux
An overview of recent data regarding the renal effects of SGLT2 inhibitors, GLP-1 RAs and DPP-4s. After a 5 minute data summary, Professor Le Roux provides his insight in helping patients achieve multifactorial treatment targets.
An overview of new and recent data presented during ADA 2019. This includes:
REWIND - the CVOT for dulaglutide
CARMELINA - the CVOT for linagliptin
CAROLINA - an active comparison CVOT studying linagliptin vs glimepiride
PIONEER 6 - the CVOT for oral semaglutide
DECLARE-TIMI 58 - the CVOT for dapagliflozin
Featuring an interview with Professor Steve Bain.
A highlight of PIONEER trial results, released during ADA 2019. This includes:
PIONEER 2 - Oral semaglutide vs empagliflozin
PIONEER 3 - Oral semaglutide vs sitagliptin
PIONEER 4 - Oral semaglutide vs liraglutide
PIONEER 5 - Oral semaglutide in patients with established kidney disease
PIONEER 6 - The CVOT for oral semaglutide
Featuring an interview with Professor Steve Bain